View : 21 Download: 0

Early imatinib mesylate-induced hepatotoxicity in chronic myelogenous leukaemia

Title
Early imatinib mesylate-induced hepatotoxicity in chronic myelogenous leukaemia
Authors
Kong J.H.Yoo S.-H.Lee K.E.Nam S.H.Kwon J.M.Lee S.M.Chang H.J.Choi M.Y.Cho M.S.Mun Y.-C.Nam E.Lee S.N.Seong C.-M.
Ewha Authors
이순남성주명조민선이경은문영철남은미
SCOPUS Author ID
이순남scopus; 성주명scopus; 조민선scopus; 이경은scopus; 문영철scopus; 남은미scopus
Issue Date
2007
Journal Title
Acta Haematologica
ISSN
0001-5792JCR Link
Citation
vol. 118, no. 4, pp. 205 - 208
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
Imatinib mesylate is the first molecule of targeted therapy in chronic myelogenous leukaemia inhibiting constitutively activated BCR-ABL kinase. There are no long-term follow-up studies of large sample sizes to assess the toxicity of the use of imatinib mesylate over 10 years. Several cases of hepatotoxicity, including fatal liver failure, have been associated with the long-term use of imatinib mesylate. We report here on a patient who experienced immediate dominant cholestatic damage of the liver and mild hepatocyte damage during imatinib mesylate therapy. This differs from most reports showing dominantly acute hepatitis with necrosis associated with the use of imatinib mesylate. Copyright © 2007 S. Karger AG.
DOI
10.1159/000111092
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE